Cargando…
HDAC2 as a target for developing anti-cancer drugs
Histone deacetylases (HDACs) deacetylate histones H3 and H4. An imbalance between histone acetylation and deacetylation can lead to various diseases. HDAC2 is present in the nucleus. It plays a critical role in modifying chromatin structures and regulates the expression of various genes by functioni...
Autores principales: | Jo, Hyein, Shim, Kyeonghee, Kim, Han-Ul, Jung, Hyun Suk, Jeoung, Dooil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030825/ https://www.ncbi.nlm.nih.gov/pubmed/36968022 http://dx.doi.org/10.1016/j.csbj.2023.03.016 |
Ejemplares similares
-
Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
por: Jo, Hyein, et al.
Publicado: (2022) -
Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics
por: Jo, Hyein, et al.
Publicado: (2022) -
The Potential of Senescence as a Target for Developing Anticancer Therapy
por: Jo, Hyein, et al.
Publicado: (2023) -
Roles of RNA Methylations in Cancer Progression, Autophagy, and Anticancer Drug Resistance
por: Jo, Hyein, et al.
Publicado: (2023) -
Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy
por: Shim, Kyeonghee, et al.
Publicado: (2023)